/

Empresas

Av

No verificado

Avenzo Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

22 Comunicados de prensa

Ver todos los comunicados de prensa

01/06/2026

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

28/05/2026

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Eventos

Industria

Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

28/04/2026

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

21/04/2026

Eventos

Industria

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

11/12/2025

Industria

Eventos

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

24/11/2025

Oncología

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Industria

Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

19/11/2025

Oncología

Material médico sanitario

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Mercado laboral

Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

10/11/2025

Oncología

Salud

Higiene alimentaria

Sanidad

Medicina - Varios

Farmacéutica

Biotecnología

Industria

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

30/10/2025

Eventos

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

29/09/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

Fuente

Avenzo Therapeutics, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0